Parexel Appoints Dr. Charlotte Moser as Chief Medical Officer to Drive Global Innovation in Clinical Research

Parexel has appointed Dr. Charlotte Moser as its new Chief Medical Officer, a strategic move that underscores the CRO’s continued commitment to advancing patient-centric clinical research. With more than 25 years in the life sciences industry — including biotech leadership and hands-on experience as an oncologist — Dr. Moser is poised to shape Parexel’s global medical and scientific strategies. CEO Peyton Howell noted, “Dr. Moser not only brings deep clinical knowledge but also a compassionate approach to care, aligning perfectly with our mission to keep patients at the core of drug development.”

Dr. Moser’s arrival signals a renewed focus on innovation in trial design and regulatory science. Having led clinical development efforts at companies like Celcuity Inc. and collaborated closely with global regulators, her expertise spans both the scientific and strategic sides of drug development. She now joins Parexel to lead its diverse clinical research portfolio, aiming to accelerate breakthrough therapies across multiple therapeutic areas. “I’m excited to help bring transformative treatments to patients around the world,” she said, reflecting on her new role.